Population entropy in APP/PS1 mice is decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms. by Janaína de Pina Carvalho (12152812)

Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1. by Udaysankar Chockanathan (18510288)

“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10⁻⁶, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 295 units from 5 recording sessions, n_APP/PS1 = 167 units from 4 recording sessions). …”

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Figure 5 from Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin by Joanna Domagala (21643925)

“…MFI, mean fluorescence intensity. <b>D,</b> A schematic representation of perforin maturation. …”